Zhejiang Huahai Pharmaceutical Co., Ltd.

Equities

600521

CNE000001DL5

Pharmaceuticals

End-of-day quote Shanghai S.E. 18:00:00 2024-06-27 EDT 5-day change 1st Jan Change
17.05 CNY -0.70% Intraday chart for Zhejiang Huahai Pharmaceutical Co., Ltd. -4.64% +16.22%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Huahai Pharmaceutical's Subsidiary Terminates Listing Guidance MT
Zhejiang Huahai Pharmaceutical Co., Ltd.(SHSE:600521) dropped from SSE 180 Index CI
Zhejiang Huahai Pharmaceutical Co., Ltd.(SHSE:600521) dropped from Shanghai Stock Exchange 180 Value Index CI
Huahai Pharmaceutical's Unit Gets Nod to Register Atomoxetine Hydrochloride Oral Solution MT
Huahai Pharmaceutical's Q1 Profit Jumps 57%, Income Up 21% MT
Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Huahai Pharmaceutical Gets Approval to Market Busulfan Injection MT
Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023. CI
Zhejiang Huahai Pharmaceutical Gets Chinese Registration Nod for Torsemide Tablets MT
Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback announced on November 14, 2023 has closed with 7,023,600 shares, representing 0.48% for CNY 99.99 million. CI
Zhejiang Huahai Pharmaceutical Forecasts Up to 65% Rise in Q1 Profit MT
Shyndec Pharmaceutical's Unit Gets Nod to Register Empagliflozin Tablets MT
Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023. CI
Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023. CI
Zhejiang Huahai Pharmaceutical Gets US FDA's Nod for Pemetrexed Disodium for Injection MT
Correction: Huahai Pharmaceutical Gets Nod to Amend Specifications for Irbesartan Tablets MT
Huahai Pharmaceutical Gets Nod to Amend Spefication for Irbesartan Tablets MT
Zhejiang Huahai Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares. CI
Huahai Pharma Selling 1.4 Billion Yuan Shares For Capacity Expansion MT
Huahai Pharma to Repurchase Up to 100 Million Yuan Shares MT
Huahai Pharma Unit Gets FDA Nod to Trial Cancer Drug MT
Zhejiang Huahai Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Huahai Pharma Registers Drug for Prostate Treatment MT
Chart Zhejiang Huahai Pharmaceutical Co., Ltd.
More charts
Zhejiang Huahai Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, manufacture and sales of generic drugs, biological drugs, innovative drugs and specialty active pharmaceutical ingredients (APIs) in multiple dosage forms. The Company's pharmaceutical preparations and APIs cover cardiovascular, mental disorder, nervous system and anti-infection fields. The Company's products include irbesartan hydrochlorothiazide tablets, losartan potassium tablets, paroxetine hydrochloride tablets, sertraline hydrochloride tablets, oseltamivir phosphate capsules, linagliptin tablets, dabigatran etexilate capsules, pemetrexed disodium for injection, esomeprazole magnesium enteric-coated capsules, febuxostat tablets and torsemide injection. The Company also provides technical services and pharmaceutical import and export trade business.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
17.05 CNY
Average target price
18.5 CNY
Spread / Average Target
+8.50%
Consensus
  1. Stock Market
  2. Equities
  3. 600521 Stock
  4. News Zhejiang Huahai Pharmaceutical Co., Ltd.
  5. Huahai Pharmaceutical Gets Approval to Market Busulfan Injection